Overview of Триган

Property	Description
Active ingredient	Dicycloverine (Dicyclomine)
Form	Tablet, capsule, oral solution, injection
Pharmacological class	Anticholinergic agent, Antispasmodic
Common use	Relief from intestinal spasms and cramping
Origin	Synthetic (tertiary amine)

What is Триган and What is its Active Substance?

Триган is a pharmaceutical product primarily identified by its active ingredient, Dicycloverine, which is internationally recognized by the non-proprietary name Dicyclomine. This medication is a synthetic compound, specifically a tertiary amine, and is typically supplied as a single-agent product containing the hydrochloride salt. The medication is available in various pharmaceutical preparations, including oral forms such as tablets, capsules, and a liquid oral solution, facilitating oral route of administration. The availability of both solid oral forms and the liquid solution targets diverse patient groups, including those who may have difficulty swallowing tablets.

What Type of Medicine is Dicycloverine?

Dicycloverine belongs to the formal pharmacological class of anticholinergic agents, and it is specifically categorized as an antispasmodic drug. Dicycloverine is a synthetic tertiary amine compound used to treat functional bowel disorders. This compound is indexed under the Anatomical Therapeutic Chemical (ATC) classification code A03AA07. The agent is used to manage conditions involving excessive motility.

What is the General Purpose of Antispasmodic Agents?

The general purpose of this type of antispasmodic agent is to relieve pain and discomfort by promoting the relaxation of smooth muscle, particularly in the walls of the gastrointestinal system. Dicycloverine is an agent used primarily to reduce symptoms of intestinal hyperactivity, such as acute spasms. The primary mechanism principle involves blocking the action of acetylcholine, the chemical messenger that signals the muscles to contract irregularly or too forcefully. By calming the hyperactive movement of the gut, the medication provides relief from abdominal pain and the intense, involuntary contractions (spasms) characteristic of functional disturbances of GI motility.

What side effects are possible with Триган?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety statements for Триган (a combination product typically containing dicyclomine and a pain reliever), based on authoritative government regulatory sources. This information is non-advisory and focuses strictly on documented risks.

Documented Adverse Reactions

Side effects are classified by how often they occur according to regulatory standards:

Frequency Category	Examples of Documented Side Effects
Very Common ( ge 10% )	Dry mouth, dizziness, blurred vision
Common ( 1% to 10% )	Nausea, drowsiness (somnolence), asthenia (weakness), nervousness
Rare ( <0.1% )	Rash, headache, sedation

System-Organ Classes (SOCs)

Adverse effects are categorized by the body system affected, including Nervous System Disorders (e.g., dizziness, somnolence), Gastrointestinal Disorders (e.g., dry mouth, constipation), Eye Disorders (e.g., blurred vision), and Cardiac Disorders (e.g., tachycardia).

Serious Adverse Reactions and Restrictions

Serious Adverse Reactions that are clinically significant include Toxic Megacolon (risk in severe ulcerative colitis), Anticholinergic Toxicity (severe confusion, delirium), Heat Prostration (due to reduced sweating), and Severe Breathing Problems/Seizures in infants. Blood disorders and liver toxicity are associated with the paracetamol component.

Safety Restrictions (Contraindications) prohibit the use of Триган in patients with certain conditions, including Glaucoma, Myasthenia Gravis, Obstructive Diseases (such as uropathy or GI obstruction), and Infants under 6 months due to critical safety risks.

Overdose and Emergency Response

Overdose and When to Seek Help

Any suspected overdose with Триган (Dicycloverine) requires immediate medical attention. Regulatory guidelines emphasize that a poison control center or emergency services must be contacted at once if an overdose is suspected, and the drug should be immediately discontinued.

Documented Manifestations and Severe Outcomes

The official overdose profile is defined by severe anticholinergic toxicity. Manifestations include CNS stimulation, such as headache, dizziness, confusion, and potential convulsions. Systemic signs include dilated pupils, blurred vision, dry mouth, and hot, dry skin.

Severe outcomes documented in official labeling include curare-like action, leading to significant muscular weakness and potential paralysis. Infants less than six months of age are specifically documented to be at high risk for serious respiratory symptoms, seizures, coma, and death from exposure. Older adults may be more prone to confusion and psychosis during toxicity.

Officially Described Management

Management procedures described in regulatory sources include supportive measures such as gastric lavage and the administration of activated charcoal to reduce drug absorption. The use of sedatives may be required to control overt signs of excitement. A parenteral cholinergic agent is officially documented as an antidote that may be administered if clinically indicated.

Therapeutic Uses of Триган

What Триган Treats: Main Uses and Benefits

Dicyclomine, the active ingredient in Триган, is indicated for the treatment of patients with functional bowel/irritable bowel syndrome. The medication is relevant in contexts where supportive symptom management is appropriate, primarily to ease the symptom clusters that interfere with daily comfort.

This medication is commonly used across conditions involving episodic or fluctuating manifestations, such as Irritable Bowel Syndrome (IBS). It is applied in addressing manifestations that include acute abdominal pain, colicky cramping, and generalized digestive discomfort or bloating that are symptoms of increased neurological or muscular activity. Its use may assist with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods. The medication is applied when appropriate for managing symptoms that create noticeable physiological strain, which may support easing the overall symptom burden.

Quick Fact: Symptomatic Relief for Spasms

Regulatory References

U.S. National Library of Medicine DailyMed

Eligibility and Restrictions for Use

Dicycloverine (the active ingredient in Триган) is approved primarily for adults diagnosed with functional bowel/irritable bowel syndrome. However, its use is strictly defined by numerous regulatory limitations and absolute contraindications as stated in official labeling.

Populations for Whom Use is Prohibited (Contraindicated)

The medicine must not be used in infants less than 6 months of age and in nursing mothers (women who are human milk feeding). Absolute contraindications also apply to patients with a known history of hypersensitivity to the drug.

Use is prohibited in patients with pre-existing mechanical obstructions or specific severe chronic conditions:

Obstructive disease of the gastrointestinal tract or obstructive uropathy
Glaucoma or Myasthenia Gravis
Severe ulcerative colitis or reflux esophagitis
Unstable cardiovascular status in acute hemorrhage

Populations for Whom Use is Restricted or Limited

Use is limited in other groups where conditional application or caution is required:

Pediatric Patients (> 6 months): Safety and effectiveness have not been established.
Older Adults (Geriatric): Use requires caution due to potential increased susceptibility to effects.
Organ/Comorbidity Restrictions: Use requires caution in patients with hepatic disease, renal disease, various cardiac disorders, or prostatic hypertrophy.
Pregnancy: Use is advised only if clearly needed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents establish Dicycloverine's interaction profile based on its anticholinergic activity and its effect on gastrointestinal motility.

Contraindicated Combination

Pramlintide is a formally contraindicated combination due to the risk of synergistic inhibition of gastrointestinal motility.

Additive and Antagonistic Effects

Co-administration with other anticholinergic agents (including Class I Antiarrhythmics, Antihistamines, Antipsychotic Agents, MAO Inhibitors, and Narcotic Analgesics) may result in additive anticholinergic adverse effects. Furthermore, Dicycloverine may antagonize the therapeutic effects of Antiglaucoma Agents and prokinetic agents such as Metoclopramide.

Absorption and Timing Constraints

Interactions affecting drug absorption require specific timing. Antacids may interfere with Dicycloverine’s own absorption; therefore, simultaneous use must be avoided. The co-administration of Dicycloverine with slowly dissolving dosage forms of Digoxin may lead to increased serum digoxin concentration dueosed to reduced transit time through the digestive system. Ingestion of Alcohol may also add to the drug’s potential for drowsiness through additive Central Nervous System (CNS) depression. Regulatory data notes that the geriatric population may have an increased susceptibility to the additive CNS-related adverse effects arising from these pharmacodynamic interactions.

Mechanism of Action

How Триган Works: Mechanism of Action

Visceral Spasmolysis via PDE4 Inhibition

The drug's mechanism involves a dual approach, initiated peripherally by drotaverine. This compound functions as a selective inhibitor of the Phosphodiesterase 4 (PDE4) enzyme, primarily targeting smooth muscle cells in visceral organs. Inhibition of PDE4 elevates intracellular concentration of cyclic adenosine monophosphate ( cAMP). This cascade alters the distribution of Ca^2+ within the cell, reducing its availability for the contractile apparatus. The resultant physiological consequence is the relaxation of internal organ muscle fibers (spasmolysis).

Central Pain Signal Modulation

Simultaneously, paracetamol acts predominantly within the Central Nervous System (CNS). It functions as an inhibitor of specific central cyclooxygenase (COX) enzyme isoforms, which suppresses the synthesis and concentration of Prostaglandin E2 ( PGE2). The suppression of PGE2 in the hypothalamus leads to the re-setting of the body's thermoregulatory center. In the spinal cord, this action modulates central nociceptive processing, leading to the dampening of ascending pain signals.

Dosage and Administration Information

How to use Tigan (Trimethobenzamide Hydrochloride)

Administration instructions for this product vary by dosage form. Patients should confirm the specific instructions with their healthcare provider and dispensing pharmacy.

Oral Capsules (300 mg)

Administration Scope	General Guidelines
Route	Oral (by mouth)
Adult Dosing	One 300 mg capsule
Frequency	Three (t.i.d.) or four (q.i.d.) times per day
Timing	Not specified in relation to meals

Injectable Form (200 mg/2 mL)

Administration Scope	General Guidelines
Route	Intramuscular (IM) injection only (Not for intravenous use)
Adult Dosing	2 mL (200 mg)
Frequency	Three (t.i.d.) or four (q.i.d.) times per day
Procedural Step	Administer deep into the upper outer quadrant of the gluteal region.
Age-Group Rule	Injectable form is not for use in pediatric patients.

Rectal Suppositories (200 mg)

Administration Scope	General Guidelines
Route	Rectal
Adult Dosing	One 200 mg suppository
Children 30 to 90 lbs	One-half to one suppository (100-200 mg)
Children under 30 lbs	One-half suppository (100 mg)
Frequency	Three (t.i.d.) or four (q.i.d.) times per day
Age-Group Rule	Suppositories are contraindicated in premature or newborn infants.

Connection to the Overall Use Protocol:

The use protocol is segmented by the physical drug form—capsule, injection, or suppository—with specific weight-based dosing and restrictions for pediatric use. The instructions establish the dose, administration route, and maximum daily frequency that apply for patient use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Триган (Dicycloverine)

Evidence for Use in Irritable Bowel Syndrome (IBS) Symptoms

Research exploring Dicycloverine was studied for short-term management of IBS symptoms, a condition characterized by fluctuating or episodic manifestations of discomfort in the digestive tract. The core evidence for this use comes mainly from older, short-term randomized controlled trials (RCTs). These studies were designed to explore how symptoms changed over defined, brief time intervals by evaluating Dicycloverine against a control.

In these trials, researchers tracked patient-reported experiences, focusing on outcomes related to physical discomfort, particularly changes in the severity and frequency of abdominal pain. Findings describe patterns observed in these small, short-term studies, which contribute to the broader evidence landscape on IBS symptoms.

Long-term Studies and Follow-up Duration

Most research supporting the use of Dicycloverine has focused exclusively on short-term symptom changes. The original regulatory trials observed responses over defined time intervals, often with follow-up durations that were limited, such as short periods of two weeks. Because the initial studies were short-term, there is limited information for long-term outcomes regarding the medication. Long-term outcomes regarding the sustained effects, maintenance of relief, or symptom progression are not fully established by the existing published research.

What is Still Uncertain About the Research for Dicycloverine

The overall evidence describes what is known—and what is still uncertain. Scientific bodies often conclude that the certainty remains low for this type of medication within the antispasmodic class, primarily because the supporting trials are decades old and generally have modest sample sizes. Furthermore, comparative evidence is lacking. Research does not frequently or consistently examine how Dicycloverine compares to other pharmacological agents studied for IBS symptoms.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Триган (FAQ)

Q: Is Триган a painkiller or an antispasmodic, or both?

According to official product information, this medicine is considered a combination product. It contains dicycloverine, which acts as an antispasmodic (to relax smooth muscles in internal organs), and paracetamol, which is a recognized analgesic (pain reliever). This composition indicates that the product is intended to address both muscle spasms and associated pain signals.

Q: Is Триган similar to other common over-the-counter pain relievers?

One of the active components in this medicine is paracetamol, which is an ingredient found in many common over-the-counter pain relievers. However, the medicine also includes an antispasmodic agent, dicycloverine. This dual composition means the product is in a different pharmacological class from simple analgesics, as its purpose is to specifically target internal organ muscle spasms.

Q: Can Триган cause drowsiness or affect my ability to drive?

Official warnings indicate that caution is advised regarding activities like driving or operating machinery that require full mental alertness. Side effects documented in regulatory sources include dizziness, drowsiness (somnolence), and blurred vision.

Q: What are the most common side effects of Триган mentioned by users?

The official regulatory safety documents classify the most frequently documented adverse effects as Very Common or Common. These commonly reported effects include dry mouth, dizziness, blurred vision, nausea, and drowsiness. These are the reactions that occurred most frequently during clinical testing.

Q: Are there any specific foods or drinks I should avoid while using Триган?

Regulatory warnings specifically advise avoiding the consumption of alcohol while taking this medicine due to the potential for increased drowsiness. Official guidelines also state that the co-administration of antacids must be avoided due to potential interference with the medicine's absorption.

Q: Can Триган be taken on an empty stomach?

The official dosing and administration instructions for the oral forms of this medicine do not specify a required timing in relation to meals. This generally indicates that taking the medicine is not strictly limited to only after or before eating.

Q: Does Триган interact with alcohol?

Yes, official warnings specifically note that combining the medicine with alcohol may lead to an additive Central Nervous System (CNS) depressant effect. This interaction can increase the risk of side effects such as drowsiness.

Q: What are the signs of taking too much Триган?

Taking too much of this medicine can lead to symptoms related to excessive anticholinergic effects, as noted in the safety section of regulatory documents. These signs can include changes such as dilated pupils, hot and dry skin, extreme dryness of the mouth, dizziness, or states of confusion.

Q: Are there different strengths of Триган available?

Yes, official regulatory documents indicate that the combination of active ingredients is available in different strengths and different pharmaceutical forms. These include oral capsules, injectable solutions for intramuscular use, and rectal suppositories, each having distinct dosages outlined in the product labeling.

Q: What is the recommended period of time for using Триган?

Official documentation and research summaries note that the evidence supporting the medicine's use for its primary indication (Irritable Bowel Syndrome) is based predominantly on short-term clinical trials. Long-term outcomes regarding sustained relief or symptom progression are not fully established by the existing research.

Q: Can Триган cause stomach irritation or heartburn?

Documented gastrointestinal side effects listed in official sources include nausea, constipation, and dry mouth. While these are noted, official regulatory documents do not commonly list heartburn or general stomach irritation as frequent side effects.

Q: Is there any research evidence supporting the combination of ingredients in Триган?

The medicine’s active ingredients are documented to work via two distinct pharmacological actions: one for smooth muscle relaxation and one for pain relief. While studies exist for the individual components, research summaries focus primarily on the use of the antispasmodic agent for symptoms related to the digestive system.

Q: Can Триган be used for headaches or migraines?

The official indications for the use of this medicine are limited to the management of stomach cramps, pain from biliary or renal colic, and symptoms associated with functional bowel disorders. It is not listed for the treatment of common headaches or migraines in regulatory documentation.

Q: Can Триган affect the results of any common lab tests?

Yes, official regulatory labels for the components of this medicine indicate that some ingredients may interfere with the results of certain laboratory tests. For example, the paracetamol component may potentially influence tests for substances like uric acid or blood glucose.

Q: Does Триган contain any ingredients that might be considered stimulants?

No, based on the documented composition and pharmacological classification, the active ingredients—dicycloverine (antispasmodic) and paracetamol (analgesic)—do not belong to the pharmacological class of stimulant medicines.

Q: Can Триган cause changes in vision?

Yes, regulatory documents list disturbances related to vision as possible adverse effects. Specifically, blurred vision is an effect included in the official adverse reaction list.

Q: Is the research evidence for Триган based on long-term or short-term studies?

Official documentation, including clinical trial summaries, indicates that the evidence supporting the medicine's use is based mainly on short-term clinical trials with limited follow-up duration.

Q: Is Триган effective for pain related to nerve issues?

The documented mechanisms of action focus on relaxing smooth muscle spasms and dampening central pain signals. The official uses are limited to conditions involving these two areas, such as pain from visceral spasms, and do not include conditions primarily related to nerve issues.

Q: Is it okay to take Триган if I am already taking an antidepressant?

Regulatory documents include a general warning that combining the medicine with other anticholinergic agents may result in additive anticholinergic adverse effects. Certain classes of medicines, such as MAO inhibitors, are listed among those that may have this additive effect.

Q: Is Триган suitable for treating muscle cramps not related to the digestive system?

The antispasmodic component in this medicine is primarily intended to relax smooth muscle fibers, especially those found in the walls of the internal organs (viscera). The official indications for use are focused on conditions involving the digestive and urinary tracts.

How should Триган be stored and disposed of?

How to Store and Dispose of Триган (Dicycloverine)

The official storage requirements for Dicycloverine (Триган) mandate that the medication be stored at Controlled Room Temperature, specifically between 20^circC and 25^circC (68^circF and 77^circF). Excursions are permitted between 15^circC and 30^circC.

Mandatory Handling and Protection

Temperature Restrictions: The liquid forms, such as the oral solution and injection, must adhere to the instruction: Do not freeze.
Container and Environment: Oral dosage forms must be protected from moisture and dispensed in a tight, light-resistant container. All containers must be kept tightly closed to maintain product stability.
Child Safety: All forms of the medication must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Dicycloverine should be disposed of according to official regulatory guidelines. If a drug take-back program is unavailable, the medication should be mixed with an undesirable substance, sealed in a container, and discarded in the household trash to prevent accidental exposure.

Триган